You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 825 α-CD38 therapy reverses α-PD1 resistance when used in a proper biologic schedule; explaining and overcoming previous failures of the combination in clinical trials

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Combination Immunotherapies
825 α-CD38 therapy reverses α-PD1 resistance when used in a proper biologic schedule; explaining and overcoming previous failures of the combination in clinical trials

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023824012
Dec 202356012
Jan 20249305
Feb 202410006
Mar 2024106012
Apr 20247408
May 20246403
Jun 20243001
Jul 20243906
Aug 20242807
Sep 20247604
Oct 20248007
Nov 20248208
Dec 20248006
Jan 202513205
Feb 20252206
Mar 2025005
Apr 2025006
May 2025006
Jun 2025003
Total18860128